Home › Funds › Rhenman & Partners Asset Management AB › REGN

Rhenman & Partners Asset Management AB position in REGN

REGENERON PHARMACEUTICALS · Health Care

Rhenman & Partners Asset Management AB reported holding 19,340 shares of REGN (REGENERON PHARMACEUTICALS) in its Q3 2026 13F filing — a position valued at US$14.7M, representing 1.62% of its reported portfolio and ranking #22 among its reported holdings. Rhenman & Partners Asset Management AB has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)19.34K sh
Reported value held$14.66M
Portfolio Weight1.62%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Rhenman & Partners Asset Management AB's REGN position evolved

Rhenman & Partners Asset Management AB first disclosed a stake in REGN in Q3 2023 at 40,000 shares (US$32.9M). The position peaked in Q4 2025 at 61,400 shares, worth US$47.4M. Across 13 filings, Rhenman & Partners Asset Management AB increased the stake 4 time(s), trimmed it 8 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 19,340 shares valued at US$14.7M — a reduction of -8,050 shares quarter over quarter.. Notable position changes include a 30% increase in Q3 2025 (shares rose 36% over the following quarter), a 70% increase in Q4 2025 (shares were roughly flat over the following quarter), a 43% trim in Q2 2026 (shares rose 22% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 40.00K $32.92M New
Q4 2023 39.00K $34.25M Reduce
Q1 2024 34.30K $33.01M Reduce
Q2 2024 32.00K $33.63M Reduce
Q3 2024 39.00K $41.00M Add
Q4 2024 43.46K $30.96M Add
Q1 2025 31.75K $20.14M Reduce
Q2 2025 27.70K $14.54M Reduce
Q3 2025 36.10K $20.30M Add
Q4 2025 61.40K $47.39M Add
Q1 2026 48.10K $37.16M Reduce
Q2 2026 27.39K $17.08M Reduce
Q3 2026 19.34K $14.66M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About REGN and 13F data

REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 29 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), Franklin Resources (US$2.75B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding REGN

All REGN fund holders →

FAQ

How long has Rhenman & Partners Asset Management AB held REGN?

Rhenman & Partners Asset Management AB has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Rhenman & Partners Asset Management AB's current position in REGN?

As of Q3 2026, Rhenman & Partners Asset Management AB holds 19.34K shares of REGN (REGENERON PHARMACEUTICALS), valued at $14.66M, representing 1.62% of its reported portfolio and ranking #22.

Has Rhenman & Partners Asset Management AB been buying or selling REGN?

In the latest 13F filing (Q3 2026), Rhenman & Partners Asset Management AB reduced its position in REGN. The position peaked in Q4 2025 at 61.40K shares.

Which other funds hold REGN?

Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, Franklin Resources, among 29 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.